• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue.乳腺癌幸存者的萎缩性阴道炎:一个棘手的生存问题。
J Pers Med. 2015 Mar 25;5(2):50-66. doi: 10.3390/jpm5020050.
2
Atrophic vaginitis.萎缩性阴道炎。
Dermatol Ther. 2010 Sep-Oct;23(5):514-22. doi: 10.1111/j.1529-8019.2010.01354.x.
3
Management of genitourinary syndrome of menopause in breast cancer survivors: An update.乳腺癌幸存者绝经后泌尿生殖综合征的管理:最新进展
World J Clin Oncol. 2022 Feb 24;13(2):71-100. doi: 10.5306/wjco.v13.i2.71.
4
Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial.用于控制乳腺癌幸存者萎缩性阴道炎的阴道 pH 值平衡凝胶:一项随机对照试验。
Obstet Gynecol. 2011 Apr;117(4):922-927. doi: 10.1097/AOG.0b013e3182118790.
5
Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy.女性癌症患者泌尿生殖系统绝经综合征的管理:关注阴道激素治疗。
Am J Obstet Gynecol. 2020 Feb;222(2):103-113. doi: 10.1016/j.ajog.2019.08.043. Epub 2019 Aug 29.
6
Updates on Therapeutic Alternatives for Genitourinary Syndrome of Menopause: Hormonal and Non-Hormonal Managements.更年期泌尿生殖综合征治疗选择的最新进展:激素及非激素管理
J Menopausal Med. 2021 Apr;27(1):1-7. doi: 10.6118/jmm.20034.
7
Vaginitis.阴道炎。
Am Fam Physician. 2011 Apr 1;83(7):807-15.
8
17β-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis.17β-雌二醇阴道片与结合雌激素阴道乳膏治疗绝经后萎缩性阴道炎的比较。
Menopause. 2018 Nov;25(11):1208-1213. doi: 10.1097/GME.0000000000001220.
9
17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis.17β-雌二醇阴道片与结合马雌激素阴道乳膏治疗绝经后萎缩性阴道炎的比较
Menopause. 2000 May-Jun;7(3):156-61. doi: 10.1097/00042192-200007030-00005.
10
Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy.接受芳香化酶抑制剂治疗的激素受体阳性乳腺癌患者使用阴道雌激素产品的情况。
Breast Cancer Res Treat. 2016 Jun;157(2):203-210. doi: 10.1007/s10549-016-3827-7. Epub 2016 May 13.

引用本文的文献

1
Efficacy of Non-Invasive Monopolar Radiofrequency for Treating Genitourinary Syndrome of Menopause: A Prospective Pilot Study.非侵入性单极射频治疗绝经后泌尿生殖综合征的疗效:一项前瞻性试点研究。
Clin Pract. 2025 Aug 20;15(8):155. doi: 10.3390/clinpract15080155.
2
Vaginal health in breast cancer survivors: a practical clinical approach.乳腺癌幸存者的阴道健康:一种实用的临床方法。
Ther Adv Med Oncol. 2025 Jul 10;17:17588359251344007. doi: 10.1177/17588359251344007. eCollection 2025.
3
Investigation of 's therapeutic mechanism in atrophic vaginitis based on network pharmacology and experimental validation.基于网络药理学和实验验证对[药物名称]治疗萎缩性阴道炎作用机制的研究 。 (你原文中's处应该是有具体药物名称未给出)
Front Pharmacol. 2025 May 8;16:1571976. doi: 10.3389/fphar.2025.1571976. eCollection 2025.
4
CO Laser Therapy for Genitourinary Syndrome of Menopause in Women with Breast Cancer: A Randomized, Sham-Controlled Trial.CO激光疗法治疗乳腺癌女性的绝经后泌尿生殖综合征:一项随机、假对照试验。
Cancers (Basel). 2025 Apr 6;17(7):1241. doi: 10.3390/cancers17071241.
5
Genitourinary symptoms in women with breast cancer: frequency, severity and impact.乳腺癌女性的泌尿生殖系统症状:发生率、严重程度及影响
Support Care Cancer. 2025 Mar 10;33(4):258. doi: 10.1007/s00520-025-09297-w.
6
Effects of sexual counseling and education based on self-efficacy theory on the sexual function of women with breast cancer.基于自我效能理论的性咨询与教育对乳腺癌患者性功能的影响。
BMC Womens Health. 2025 Jan 4;25(1):4. doi: 10.1186/s12905-024-03512-2.
7
Practical Guidance on the Use of Vaginal Laser Therapy: Focus on Genitourinary Syndrome and Other Symptoms.阴道激光治疗应用实用指南:聚焦于泌尿生殖综合征及其他症状
Int J Womens Health. 2024 Nov 14;16:1909-1938. doi: 10.2147/IJWH.S446903. eCollection 2024.
8
Vulvovaginal Atrophy Following Treatment for Oncogynecologic Pathologies: Etiology, Epidemiology, Diagnosis, and Treatment Options.治疗妇科肿瘤疾病后发生的外阴阴道萎缩:病因、流行病学、诊断和治疗选择。
Medicina (Kaunas). 2024 Sep 27;60(10):1584. doi: 10.3390/medicina60101584.
9
Measuring serum oestrogen levels in breast cancer survivors using vaginal oestrogens: a systematic review.使用阴道雌激素测量乳腺癌幸存者的血清雌激素水平:系统评价。
Breast Cancer Res Treat. 2024 Jul;206(2):215-226. doi: 10.1007/s10549-024-07364-0. Epub 2024 May 23.
10
Herbal Treatment of Female Urogenital Atrophy: A Retrospective Cohort Analysis.女性泌尿生殖系统萎缩的草药治疗:一项回顾性队列分析。
Complement Med Res. 2024;31(2):124-132. doi: 10.1159/000536193. Epub 2024 Jan 11.

本文引用的文献

1
Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors.芳香化酶抑制剂辅助治疗的前两年期间的性功能问题。
J Sex Med. 2014 Dec;11(12):3102-11. doi: 10.1111/jsm.12684. Epub 2014 Aug 21.
2
Cancer treatment and survivorship statistics, 2014.癌症治疗和生存统计,2014 年。
CA Cancer J Clin. 2014 Jul-Aug;64(4):252-71. doi: 10.3322/caac.21235. Epub 2014 Jun 1.
3
Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast.奥司米芬治疗与外阴和阴道萎缩相关的性交困难:对骨骼和乳腺的潜在益处。
Int J Womens Health. 2013 Sep 25;5:605-11. doi: 10.2147/IJWH.S39146.
4
Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.绝经后妇女阴道和外阴萎缩的管理:北美绝经学会 2013 年立场声明。
Menopause. 2013 Sep;20(9):888-902; quiz 903-4. doi: 10.1097/GME.0b013e3182a122c2.
5
Profile of ospemifene in the breast.在乳房方面的奥昔孕诺的概况。
Reprod Sci. 2013 Oct;20(10):1130-6. doi: 10.1177/1933719113497290. Epub 2013 Aug 13.
6
Premature menopause in young breast cancer: effects on quality of life and treatment interventions.年轻乳腺癌患者的早发性绝经:对生活质量的影响及治疗干预。
J Thorac Dis. 2013 Jun;5 Suppl 1(Suppl 1):S55-61. doi: 10.3978/j.issn.2072-1439.2013.06.20.
7
Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.乳腺癌女性的更年期症状发生率及其对依从性的影响。
Climacteric. 2014 Jun;17(3):252-9. doi: 10.3109/13697137.2013.819327. Epub 2013 Aug 25.
8
Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.绝经后妇女的外阴和阴道萎缩:REVIVE(真实女性对绝经后阴道变化治疗选择的观点)调查的结果。
J Sex Med. 2013 Jul;10(7):1790-9. doi: 10.1111/jsm.12190. Epub 2013 May 16.
9
The acceptability, feasibility, and efficacy (phase I/II study) of the OVERcome (Olive Oil, Vaginal Exercise, and MoisturizeR) intervention to improve dyspareunia and alleviate sexual problems in women with breast cancer.OVERcome(橄榄油、阴道锻炼和保湿剂)干预措施改善乳腺癌女性性交困难和缓解性问题的可接受性、可行性和疗效(I/II 期研究)。
J Sex Med. 2013 Oct;10(10):2549-58. doi: 10.1111/jsm.12156. Epub 2013 May 1.
10
Resistance and barriers to local estrogen therapy in women with atrophic vaginitis.萎缩性阴道炎女性应用局部雌激素治疗的抵抗和障碍。
J Sex Med. 2013 Jun;10(6):1567-74. doi: 10.1111/jsm.12120. Epub 2013 Mar 27.

乳腺癌幸存者的萎缩性阴道炎:一个棘手的生存问题。

Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue.

作者信息

Lester Joanne, Pahouja Gaurav, Andersen Barbara, Lustberg Maryam

机构信息

Clinical Research Nurse Practitioner, Division of Surgical Oncology, The Ohio State University, Columbus, OH 43210, USA.

Department of Psychology, The Ohio State University, Columbus, OH 43210, USA.

出版信息

J Pers Med. 2015 Mar 25;5(2):50-66. doi: 10.3390/jpm5020050.

DOI:10.3390/jpm5020050
PMID:25815692
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4493485/
Abstract

Management of breast cancer includes systematic therapies including chemotherapy and endocrine therapy can lead to a variety of symptoms that can impair the quality of life of many breast cancer survivors. Atrophic vaginitis, caused by decreased levels of circulating estrogen to urinary and vaginal receptors, is commonly experienced by this group. Chemotherapy induced ovarian failure and endocrine therapies including aromatase inhibitors and selective estrogen receptor modulators can trigger the onset of atrophic vaginitis or exacerbate existing symptoms. Symptoms of atrophic vaginitis include vaginal dryness, dyspareunia, and irritation of genital skin, pruritus, burning, vaginal discharge, and soreness. The diagnosis of atrophic vaginitis is confirmed through patient-reported symptoms and gynecological examination of external structures, introitus, and vaginal mucosa. Lifestyle modifications can be helpful but are usually insufficient to significantly improve symptoms. Non-hormonal vaginal therapies may provide additional relief by increasing vaginal moisture and fluid. Systemic estrogen therapy is contraindicated in breast cancer survivors. Continued investigations of various treatments for atrophic vaginitis are necessary. Local estrogen-based therapies, DHEA, testosterone, and pH-balanced gels continue to be evaluated in ongoing studies. Definitive results are needed pertaining to the safety of topical estrogens in breast cancer survivors.

摘要

乳腺癌的治疗包括化疗和内分泌治疗等系统疗法,这些疗法可能导致多种症状,进而损害许多乳腺癌幸存者的生活质量。该群体常出现由循环雌激素水平降低至泌尿和阴道受体而引起的萎缩性阴道炎。化疗导致的卵巢功能衰竭以及包括芳香化酶抑制剂和选择性雌激素受体调节剂在内的内分泌治疗,可能引发萎缩性阴道炎的发作或加重现有症状。萎缩性阴道炎的症状包括阴道干燥、性交困难、生殖器皮肤刺激、瘙痒、灼痛、阴道分泌物增多和疼痛。萎缩性阴道炎的诊断通过患者自述症状以及对外阴结构、阴道口和阴道黏膜的妇科检查来确认。生活方式的改变可能有所帮助,但通常不足以显著改善症状。非激素阴道治疗可通过增加阴道湿度和液体来提供额外缓解。乳腺癌幸存者禁用全身雌激素治疗。有必要继续研究萎缩性阴道炎的各种治疗方法。正在进行的研究中持续评估基于局部雌激素的疗法、脱氢表雄酮、睾酮和pH平衡凝胶。需要获得关于局部雌激素在乳腺癌幸存者中安全性的确切结果。